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Abstract
Early brain development is a critical epoch for the development of autism spectrum disorder (ASD). In vivo animal
models have, until recently, been the principal tool used to study early brain development and the changes
occurring in neurodevelopmental disorders such as ASD. In vitro models of brain development represent a
significant advance in the field. Here, we review the main methods available to study human brain development
in vitro and the applications of these models for studying ASD and other psychiatric disorders. We discuss the main
findings from stem cell models to date focusing on cell cycle and proliferation, cell death, cell differentiation and
maturation, and neuronal signaling and synaptic stimuli. To be able to generalize the results from these studies, we
propose a framework of experimental design and power considerations for using in vitro models to study ASD.
These include both technical issues such as reproducibility and power analysis and conceptual issues such as the
brain region and cell types being modeled.
Early development as a critical period for ASD
susceptibility
Several emerging lines of evidence have established that
disruption of prenatal brain development is a major risk
pathway for development of autism spectrum disorder
(ASD) [1–3]. Many of the genes found to be associated
with ASD are highly co-expressed in both neural pro-
genitors and newborn neurons and peak in expression
during prenatal brain development [1–4]. Moreover,
work integrating genome wide association study
(GWAS) results [1] with gene regulatory interactions, in-
cluding expression quantitative trait loci (eQTL) [5] and
3D chromatin structure, demonstrates enrichment of
ASD risk alleles in human-specific gene enhancers active
in fetal brain and, in particular, in neural progenitors [6].
At the neuropathological level, studies have identified
abnormalities in cerebral cortex in individuals with ASD,
including smaller neurons, a higher abundance of neu-
rons, ectopic cells, and dendritic abnormalities, which are
likely to be caused by abnormalities in cortical develop-
ment [7]. Neuroimaging studies found changes in cortical
surface area in ASD as early as 6 months postnatally, likely
due to prenatal abnormalities in cortical development [8].
Another line of evidence comes from studies of environ-
mental exposures associated with ASD. These include
studies associating prenatal exposure to valproate [9], as
well as to maternal bacterial [10] and viral infections dur-
ing pregnancy (i.e., cytomegalovirus (CMV)) [11]. These
diverse lines of evidence implicate early cortical develop-
ment as one major convergent period of risk in the devel-
opment of ASD. Even more remarkably, late onset
disorders such as schizophrenia and bipolar disorder, as
well as non-specific risk for neuropsychiatric disorders,
have also been linked to fetal brain development—empha-
sizing the importance of development in susceptibility for
psychiatric disorders more broadly [12–16].
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Animal models
In vivo animal models are a major avenue of research
for studying early brain development and how it is al-
tered in ASD [17–21]. These models have many advan-
tages as they can be used to study the entire process of
brain development including age-dependent pathophysi-
ology [21]. They allow for manipulation of specific genes
on a homogeneous genetic background thus offering a
way to study the effects of specific genes on the tran-
scriptome, cell and circuit function, brain network activ-
ity, and behavior [17–21]. However, mouse models do
not capture primate-specific or human-specific mecha-
nisms active during early brain development or human
complex genetic risk [22]. These human-specific mecha-
nisms include many regulatory events, such as enhancer
function and enhancer-promoter interactions, which
govern gene expression in human neurogenesis and neu-
rons [6, 13, 23–27].
Primate models are being developed to address some
of these issues with mouse and other rodent models
[28–30]. However, these primate models are expensive
to develop and maintain, have a long reproductive cycle,
and require careful ethical consideration [29]. Addition-
ally, like mouse models, these models cannot yet capture
genetic background effects or the polygenic contribution
to ASD [31].
In vitro options for studying human brain
development
In vitro models allow researchers to model typical
early human brain development, as well as changes
occurring in ASD and other neurodevelopmental dis-
orders (NDDs) [32]. The advantages and disadvan-
tages of the most widely used methods have been
extensively reviewed [32–39] and are briefly summa-
rized in Table 2. We provide an overview of the vari-
ous major techniques below, which can broadly be
categorized into three major groups based on the
source of the cells used.
The first method utilizes primary human neural precur-
sor cells (phNPCs) extracted from fetal postmortem cor-
tex. These phNPCs are aggregated into neurospheres
which can be cultured for extended periods of time [40].
These neurospheres are further differentiated into neu-
rons and glia using combinations of growth factors [40,
41]. The resulting neurons closely model in vivo fetal cor-
tical development up to mid-gestation (19–24 post con-
ception weeks) [41]. The expression of a group (module)
of genes harboring de novo loss of function mutations in
ASD and related to chromatin remodeling in vivo was well
preserved in phNPCs [41]. These results are consistent
with data indicating that chromatin structure in these
neurons, as queried by ATAC-seq, highly overlaps with
in vivo patterns [12].
The second method, termed trans-differentiation, dir-
ectly induces neurons (iNs) from non-neuronal cells by
using combinations of induction factors which activate a
neuronal transcription cascade [42, 43]. This method,
which often uses combinations of transcription factors,
can quickly generate many types of iNs from somatic
cells and results in a mature post-mitotic population of
iNs without going through a neural progenitor (NPC)
stage [42, 43]. These iNs retain many of the epigenetic
marks of the source tissue [44, 45] which can capture
the epigenetic signature of aging. This can be advanta-
geous, for example, when studying neurodegenerative
diseases [46, 47]. Given this method’s speed and reliabil-
ity of generating post mitotic maturing neurons, direct
induction approaches can be advantageous, especially in
the context of high throughput screens for which speed
and reliability are paramount [42, 43, 48–55]. However,
this method does not allow for complete and faithful
modeling of fetal neuronal development, which depends
on the correct sequence of developmental steps and epi-
genetic signature [44, 45, 56, 57].
The third method relies on embryonic (ESC) or in-
duced pluripotent stem cells (iPSC) which are differenti-
ated into heterogeneous cultures and can recapitulate
different in vivo developmental stages [58]. One advan-
tage of using iPSCs over ESC is that they can be gener-
ated from cells collected directly from individuals with
ASD and can thus be used to capture both the genetic
background, as it may influence major effect mutations,
as well as idiopathic forms of ASD [32]. Another advan-
tage is that the findings from iPSC derived from individ-
uals with ASD can be integrated with available medical
records, imaging results, and family pedigree which
could supply the study with valuable phenotypic data.
One example of this integrated head size as a phenotype
to study changes occurring in individuals with ASD and
macrocephaly [59, 60]. These advantages are often also
true for iNs derived from patients [39]; however, unlike
iNs, iPSCs can recapitulate different in vivo developmen-
tal stages and have a methylation profile which resem-
bles that of ESC [61–65]. It is important to note that
iPSC do retain a small fraction of methylation markers
from the donor, which can differ between different itera-
tions of reprogramming and can depend on the source
of the reprogrammed cells used [62, 63, 65]. Addition-
ally, iPSCs tend to have lower genetic stability, some-
times leading to multiple unintended copy number
variants (CNV) and single nucleotide variants (SNV),
which necessitates whole genome sequencing to validate
each line [66].
Both ES and iPSC can be differentiated into 2-
dimensional (2D) and 3-dimensional (3D) neuronal cul-
tures. 2D cultures can be generated by adding growth
factors [67, 68] or small molecules [69, 70] to the
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medium to generate NPC, which can then be further dif-
ferentiated in neurons [39]. Direct differentiation into
neurons which does not go through a NPC stage, as
mentioned above, can also be achieved by overexpress-
ing growth factors (e.g., NGN2, or Ascl1/Dlx2) [71, 72].
This can result in a more homogenous cell population
and is highly scalable and reproducible [71, 72]. How-
ever, these mono-layer cultures do not fully capture
in vivo brain development, as they lack the dense cellular
environment of the brain which includes many synaptic
and glial junctions [32, 39, 73]. Additionally, the direct
to neuron methods may miss critical steps in the devel-
opmental trajectory of neurons where genetic risk may
be acting, making them less suited to study neurodeve-
lopment [39, 71].
3D cultures, also referred to as organoids, which cap-
ture more of the architecture (e.g., cortical layering) and
cellular environment of in vivo brain development, can
be organized by level of directed differentiation going
from less directed to highly directed differentiation [32,
33, 38, 74–76]. While all differentiations are initially
grown in neural induction media, in the less directed dif-
ferentiations, the cells are not directed to differentiate
into a specific brain region using additional factors [75,
77–80]. These differentiation methods lead to cultures
with a variety of brain regions which can be used to
study inter- and intra-regional connections [75, 81, 82].
However, these methods require careful assessment, par-
ticularly when studying disease, as regional heterogeneity
can make these cultures extremely variable, making it
difficult to compare between different cultures, even
those that are presumed replicates from the same indi-
vidual [81]. In contrast, the more directed differentiation
protocols use specific combinations of morphogens, sig-
naling molecules and growth factors to guide the cul-
tures to differentiate into a specific brain region (often
dorsal forebrain). To promote neural induction, many of
these protocols initially add different combinations of
growth factors (i.e., EGF, NT3, BDNF, and GDNF) [74,
78, 79, 83, 84]. This results in more reproducible cultures
compared to the less directed differentiation, as seen by
lower variability and more consistent cell types and cell
proportions [74, 83–86]. More recently, multiple groups
have described fusing the more directed organoids from
different brain regions together. These combined cultures,
termed assembloids, model the development of complex
interconnected regions thus more faithfully recapitulating
in vivo development and function [85, 87, 88]. For ex-
ample, the fusing of dorsal and ventral forebrain cultures
has been shown to reliably integrate interneurons into the
dorsal forebrain [85, 87, 88].
Work in 3D in vitro models of brain development is in
its early stages and more work is needed to improve
their ability to faithfully and reproducibly recapitulate
in vivo development. A recent study noted that these
cultures can show increased levels of cell stress as well
as reduced cell subtype specification compared to
in vivo [78]. A noteworthy disadvantage of these 3D cul-
tures compared to 2D cultures expressing NGN2 [71]
and iNs [42, 43] is that while cells in these 2D methods
take roughly 2 weeks (14 days) to differentiate into neu-
rons, 3D cultures typically take 2–4 months (60–120
days) to reach differentiation levels similar to mid-
gestation [74–76, 78, 83]. This makes the 3D cultures
less scalable and therefore less suited for large scale
screens [32, 33]. These longer differentiations, however,
can also be viewed as an advantage, as they can lead to
more mature cellular and transcriptomic phenotypes in
both neurons and glia [77, 84, 89].
Applications
Studying neurodevelopmental and psychiatric disorders
In vitro models can be used to study the effects of both
common and rare genetic variation on early human
brain development at a cellular and molecular level, in
both typical development and neurodevelopmental and
psychiatric disorders. Since most genetic variation re-
sides in non-coding regions, which are highly diverged
between human and rodents [90], it is necessary to use
primate or human models to understand the role of
most regulatory variation [5], especially for ASD risk
genes that are regulated by human evolved elements [6].
Moreover, studying the role of common genetic back-
ground on neurodevelopment in ASD and other psychi-
atric disorders is currently only feasible by studying
patient-derived cellular models.
Using these models, one can compare differentiated
cultures from individuals with ASD and other psychi-
atric disorders, either from those without a clearly de-
fined genetic etiology or from those with genetically
defined forms. This approach accounts for the genetic
background and, in the case of genetically defined forms,
also integrates the effects of the mutation with the gen-
etic background, giving results that can reflect the
complex genetic architecture of these disorders. A com-
plementary approach to study genetically defined forms
is to use isogenic lines in which researchers either in-
duce mutations in control lines or correct mutations in
lines derived from individuals with ASD, e.g., using
CRISPR/Cas9 methods [91]. This approach minimizes
variation caused by genetic background and directly
links the observed phenotype with the mutation [91].
Thus, it allows for direct inference of the role that ASD
risk genes play in neurodevelopment.
In addition to understanding both common and rare
genetic risk, iPSC-derived models can also be used to
study the role of environmental factors on both typical
and atypical brain development. These environmental
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factors can be extrinsic, such as organophosphates [92]
and bisphenol-A [93], or in utero factors such cortisol
levels and inflammatory factors [94, 95]. For example,
exposing neuroepithelial-like stem cells to high levels of
glucocorticoids for 48 h transiently increased intracellu-
lar reactive oxygen species concentration [96]. This ex-
posure led to persistent inhibition of neural
differentiation and increase in glial differentiation [96].
Precision medicine
Stem cell models of brain development can also be used
in the field of precision medicine [97]. Stem cell-derived
neurons could serve as a potential diagnostic tool for en-
igmatic rare diseases. In cases where whole exome se-
quencing does not yield a diagnosis, transcriptomic
analysis of relevant tissue has shown some promise [98–
101]. In cases when the relevant tissue is inaccessible
(which is the majority of cases in neurodevelopmental
and psychiatric disorders), blood transcriptomics se-
quencing has been suggested as an alternative and was
shown to be informative in 7.5–16.7% of cases [101,
102]. However, many cases still remain undiagnosed,
and it is reasonable to believe that transcriptomics se-
quencing from cells mimicking the relevant tissue by
using stem cell-derived cultures would further increase
this rate of diagnosis.
Additionally, given the high heterogeneity and polyge-
nicity of psychiatric disorders, these in vitro models
could help identify intermediate processes leading to
neuronal dysfunction [103]. Combined with genetic data,
medical record data, and imaging results, this could lead
to stratification of patient populations into more
homogenous cohorts and to development of cohort-
specific treatments [97].
Drug discovery
Stem cell-based models can also be used to screen drugs
for treatment of neurodevelopmental disorders including
ASD [91, 104]. For example, one study screened 4421
unique compounds and identified 108 compounds that
regulate neurite growth [105], a process which has been
variably linked to some forms of ASD [106]. Another
study screened a set of 50,000 compounds in neural
stem cells to find activators of FMR1, a gene silenced in
fragile X syndrome, which increases risk for ASD [107].
Similarly, a different study screened 202 compounds for
their ability to restore SHANK3 expression in SHANK3
haplo-insufficient stem cell-derived neurons [108]. Two
compounds, lithium and valproic acid (VPA), were
found to restore SHANK3 expression and increase net-
work connectivity in these neurons [108].
Additionally, stem cell-derived neurons from individ-
uals with psychiatric disorders can be used for drug dis-
covery and for tailoring drug regimens to specific
individuals or subgroups. For example, reversal of hyper-
excitability in iPSC-derived neurons from individuals
with bipolar disorder was a good predictor for the re-
sponsiveness of these individuals to lithium therapeutics
[109].
Evolution of the human brain
One other interesting emerging application is to study
the evolution of the human brain by comparing cultures
derived from human to other non-human primates
which share many of the transcriptional programs deter-
mining cell type in the developing cerebellar cortex [82,
83, 110, 111]. One study, using 2D and 3D stem cell-
derived cultures, found that differences in neuronal cell
numbers among rodents, non-human primates, and
humans could be partially explained by the differences
in the presence and length of a developmental stage of
cerebral cortex progenitor expansion that was signifi-
cantly increased in humans [111]. Supporting this find-
ing, two studies found that cellular maturation took
longer in humans organoids compared to chimpanzee
and bonobo organoids [82, 110]. Many upregulated
genes and changes in DNA accessibility in these studies
were identified as being specific to the developing hu-
man brain [82]. Additional support to the extended mat-
uration of human cells comes from co-expression
network analysis which identified human-specific tran-
scriptional changes in groups of genes related to cell
cycle and neuronal apoptosis [83].
Main findings from stem cell models of ASD to date
Two kinds of genetic modeling have been performed
using cells either from individuals whose genetic contri-
butions are unknown or undefined, so called idiopathic
[59, 60, 112–120], or from individuals harboring major
effect mutations that are presumed causal or which have
been engineered to carry these mutations. These muta-
tions include ASD-associated CNVs such as 15q11q13
deletion (Angelman syndrome) [121] and duplication
(Dup15q syndrome) [122], 22q11.2 deletion (DiGeorge
syndrome) [123, 124], 16p11.2 deletion and duplication
[125], and 15q13.3 deletion [126], as well as single-gene
mutations including SHANK3 [127–130], CHD8 [131,
132], NRXN1 [133–137], NLGN4 [138], EHMT1 (Kleef-
stra syndrome) [139], PTCHD1-AS [140], UBE3A
(Angelman’s syndrome) [141], and CACNA1C (Timothy
syndrome) [142] (summarized in Table 1). In this review,
we will not discuss fragile X syndrome, Rett’s syndrome,
and tuberous sclerosis-related autism as they have all
been extensively reviewed previously [148–154].
The majority of these studies used cells from patients,
with some also including isogenic controls [121, 127,
131, 134, 145, 146], while some studies exclusively used
induced mutations comparing them with isogenic
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control lines [132, 133, 138, 141, 147] (Table 1). Many of
the studies, from both idiopathic and genetically defined
forms of ASD, found effects in one (or more) of four
general categories of cellular biological processes: (1) cell
cycle and proliferation, (2) cell death (specifically apop-
tosis), (3) cell differentiation and maturation, and (4)
neuronal signaling and synaptic stimuli (Table 1). We
have therefore organized the results according to these
categories.
Cell cycle and proliferation
Several studies found changes in cell cycle in cells de-
rived from both individuals with idiopathic or genet-
ically defined forms of ASD. Neuronal cultures from
individuals with idiopathic ASD and macrocephaly
displayed accelerated cell cycle progression, accom-
panied by upregulation of genes involved in cell pro-
liferation in several independent studies, making this
one of the few findings to have been replicated [59,
60, 117, 119]. Two studies also found that neurons
derived from individuals with ASD but without
macrocephaly also proliferated faster [118, 120].
Conversely, genetically defined forms of ASD, muta-
tion in NRXN1, and 22q11.2 deletion showed evi-
dence of a decreased proliferation rate [124, 135,
144]. However, it is important to note that not all
studies that examined cell cycle found changes in
ASD [116, 125, 140, 143].
The acceleration in cell cycle in idiopathic ASD
supports a finding from toddlers with ASD in which
cell cycle gene networks were positively correlated
with brain volume [155]. This acceleration could ex-
plain the differences in neuronal number and brain
growth across the life span of individuals with ASD
[156], as well as the high prevalence of macrocephaly
in individuals with ASD [157]. However, an important
caveat to this finding is that these changes in cell
cycle could be an artifact stemming from confounders
within culturing conditions that are propagated due
to small sample size. To address this, larger samples
are needed with robust measures for the reproducibil-
ity of the culturing system.
Cell death
Studies in 22q11.2 deletion [144], as well as idiopathic
forms of ASD [117, 143], found an increase in cell
death—more specifically in apoptotic cell death—in ma-
ture neurons [117, 143, 144]. This increase in apoptotic
cell death has also been described in vivo in a small sam-
ple of postmortem brains from children with idiopathic
forms of ASD [158], a finding which has yet to be more
broadly investigated.
Neuronal differentiation and morphology
Studies on neurons derived from individuals with idio-
pathic ASD show conflicting results relating to neuronal
differentiation. One study performed on individuals with
macrocephaly found a general increase in the number of
neural precursor cells (NPCs) [60]. This increase was
driven by an expanded proportion of GABAergic inhibi-
tory precursors, which unexpectedly led to a reduced
number of GABAergic neurons [60]. Compared to
GABAergic inhibitory precursors, the proportion of glu-
tamatergic precursors was reduced in these cultures and
was accompanied by a decrease in the number of excita-
tory synapses [60]. The increase in the total number of
neurons was replicated in another study using 3D cul-
tures, which also found accelerated development in dif-
ferentiating excitatory neurons and more complex
neurite branching patterns [114].
However, not all studies have found the same changes
in cell proportions. One study, also based on individuals
with macrocephaly, found an increase in GABAergic cell
number accompanied by an increased number of
GABAergic synapses [59]. This study did not find any
changes in the number of excitatory glutamatergic neu-
rons and synapses [59]. More recently, this increase in
GABAergic neurons but not glutamatergic neurons, has
been partially replicated from non-macrocephalic indi-
viduals with ASD, finding an increase in GABAergic cell
markers, but no long-term changes in glutamatergic cell
markers [117]. Yet, another study found a decrease in
the total number of neurons in cultures from individuals
with ASD without macrocephaly [118]. Contrary to the
studies above which found some changes in cell propor-
tions, a study performed using iPSCs from individuals
with idiopathic ASD [116] found no change in cell pro-
portions, but rather observed a reduction in glutamater-
gic synaptogenesis. This reduction was attenuated by the
astrocytes in the culture as it was only seen when both
neurons and astrocytes were derived from the individ-
uals with ASD but not when the astrocytes were derived
from healthy individuals [116].
These often conflicting results likely arise from many
factors, ranging from etiological diversity, to small sam-
ple sizes, to differences in the culturing conditions. Un-
less one controls for the extraordinary etiological/
genetic heterogeneity by studying known mutations, bio-
logical differences between a handful of different individ-
uals with idiopathic ASD would likely swamp subtle
differences in in vitro development, especially given the
small effects sizes found in imaging studies [159]. The
small sample sizes used in these studies (3–8 affected in-
dividuals per study) could also be a cause for these
contradictory results. Small sample sizes have lower
power to detect changes, tend to overestimate effect
sizes, and can lead to low reproducibility [160]. Different
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culturing methods could also lead to very different re-
sults even when looking at the same individuals. This
was demonstrated in one study, where the ASD pheno-
type of neurite complexity and length was completely
dependent on the differentiation protocol [114]. When
the neurons were generated via NPCs using extrinsic
signals, an increase in neurites was observed, whereas
when differentiating the cells directly into neurons by
overexpressing NGN2, this phenotype could no longer
be seen [114]. In another study that also highlighted the
importance of culturing protocols, specifically the cell
composition of these cultures, the source of the astro-
cytes co-cultured with neurons (control or ASD) had a
large effect on the neuronal phenotype [116], demon-
strating the importance of considering the extracellular
environment and cell-cell communication in modeling
development. To make the results from these studies
more robust, one would ideally like to see larger, more
well-powered studies and use of different culturing sys-
tems that best mirror in vivo development. Going be-
yond technical reproducibility, the contradictory findings
in the literature emphasize that biological and genetic
variability need to be better accounted for to be able to
generalize the results. In summary, given the large het-
erogeneity and small effect sizes seen in these studies,
combined with their relatively small sample sizes and
variability in culturing methods, we find it difficult to
generalize from any of the published findings based on
studies of small numbers of patients with idiopathic
ASD.
In contrast to the variable results in idiopathic ASD,
findings from genetically defined forms of ASD are gen-
erally more coherent. This is consistent with the view-
point that the phenotypic variability seen in the
idiopathic forms of ASD is due, at least partially, to etio-
logical diversity. Several genetic forms of ASD show a
decrease in the number of neurons and synapses, includ-
ing Timothy syndrome—in which there was a decrease
in the fraction of neurons expressing lower layer
markers [142] and 22q11.2 deletion, which showed a re-
duced number of neurons accompanied by an increase
in the number of astrocytes [124]. Three studies on
NRXN1 mutations also found evidence for a decrease in
neuronal maturation [134, 135, 137], a finding which
was not replicated in a different study [136]. Similar re-
sults (downregulation of neuronal processes) were indir-
ectly observed using transcriptomic analysis from
neurons in which CHD8 was either knocked down [132]
or heterozygously deleted [131].
Neuronal morphology, and more specifically dendritic
tree morphology, was also perturbed in many of the
genetically defined forms of ASD. The size and com-
plexity of the dendritic tree was decreased in neurons
with SHANK3 [127–130]. One study also showed a
reduction in spine density [129], though this result was
not replicated by a different group [127]. Similar de-
creases in dendritic tree complexity were also found in
neurons derived from individuals with Angelman syn-
drome [122] and in one individual with a PTCHD1-AS
mutation [140]. However, not all genetic forms of ASD
followed this pattern of decreased complexity of the
dendritic tree. Notably, the 16p11.2 locus shows a dos-
age effect on the size and complexity of the dendritic
tree [125]. The dendritic length was decreased in
16p11.2 deletion and was increased in 16p11.2 duplica-
tion [125]. Additionally, in contrast to the findings with
SHANK3, SHANK2 loss of function mutations led to an
increase in the number of synapses, as well as in the
complexity of the dendritic tree [146]. Individuals with
NLGN4 [138] and one individual with a PTCHD1-AS
mutation [140] also showed an increase in the number
of synapses.
Interestingly, similar to the findings in some of
these stem cell models, gene sets related to neurons
and synaptic activity are downregulated in the post-
mortem cortex of individuals with ASD [120, 161–
166] suggesting a possible point of convergence
between some of the genetically defined and idio-
pathic forms of ASD.
Neuronal signaling and synaptic function
Dysregulation in neuronal differentiation and synaptic and
dendritic deficits may underlie the decreased spontaneous
activity and decreased excitability found in many studies.
These are often observed in neurons derived from individ-
uals with idiopathic forms of ASD [112, 116, 167], as well
as from individuals with genetically defined forms of ASD
such as SHANK3 [127, 130], 16p11.2 deletion and duplica-
tion [125], Angelman syndrome [121], Dup15q syndrome
[122], NRXN1 mutations [133, 135, 137], and PTCHD1-
AS [140]. Decreases in spontaneous neuronal activity were
also found in five out of ten genes associated with ASD
when mutations were introduced into neurons derived
from typically developing individuals (ATRX, AFF2,
KCNQ2, SCN2A, and ASTN2; see Table 1 for the full list
of genes tested) [147].
The evidence for decreased neuronal activity over-
laps with findings from transcriptomic analysis of
postmortem cortex from individuals without a clearly
defined genetic etiology and individuals with Dup15q
[161, 165, 166]. These analyses found downregulation
of gene modules related to synaptic activity and neur-
onal firing [161, 165, 166]. Combining the postmor-
tem results with results from the stem cell models
suggests that these changes in neuronal properties
start at early stages of development and may persist
throughout development. Additionally, these findings
could link the cellular and network phenotype seen in
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these cultures to the excitation-inhibition (E/I) imbal-
ance which has been proposed as an organizing
framework to understand network activity in ASD
[168].
Collectively, these studies demonstrate the poten-
tial utility of using stem cell models to study ASD by
capturing the changes in early brain developmental in
ASD at cellular and molecular resolution, but reproduci-
bility and variability remain challenges that each study
needs to address. One important caveat is that as many
of the individuals used in these studies have complex be-
havioral phenotypes and comorbidities (i.e., intellectual
disability, macrocephaly, epilepsy etc.) and more work
will be required to tease apart which of these phenotypes
are directly related to the core symptoms of ASD and
which may be related to other comorbidities.
Experimental design and power considerations
when using stem cell models to study ASD
While in vitro systems allow us to directly model human
brain development, they are only as good as their ability
to reliably reproduce processes and cell types occurring
in vivo. The first step is, therefore, to create culturing
systems that are both scalable and reproducible [83, 84,
86, 169]. A recent study has taken a step in this direction
by demonstrating that both scalability and reproducibil-
ity can be increased by using a xeno-free approach that
simplifies the differentiation protocol by not re-plating
cells or embedding them into extracellular matrices [86].
Next, as these in vitro models only approximate
in vivo brain development, it is important to ascertain
the maturity of the culture used in each study. One sys-
tem to assess the maturity of the culture uses three dif-
ferent bioinformatic tools to compare the in vitro
cultures to in vivo brain development based on their
transcriptome [41]. These genome-wide measurements
are an important unbiased complement to physiological
and morphological analysis of maturation-related
phenotypes.
Cell type composition can also have a profound effect
on the results. For example, Russo et al. [116] found that
the presence of astrocytes derived from iPSCs of individ-
uals with ASD interacted with neurons derived from the
same individual to decrease the number of excitatory
synapses [116]. It is therefore important to fully
characterize the cell types and proportions present in
the culturing system either directly by using single-cell
technologies such as single-cell RNA sequencing or flow
cytometry or indirectly using immunodetection of cell
markers. Another aspect highlighted by this study is the
importance of having as complete a representation of
cell types found in vivo as possible, as this can have a
profound change on phenotype [116, 170, 171].
One more related aspect that needs to be consid-
ered is that of the brain region being modeled. Many
brain regions are involved in different aspects of ASD
[7, 172], each with its unique cellular composition
and cytoarchitecture. It will therefore be essential to
study the specific molecular and cellular changes in
ASD in the different brain regions. As an example,
one study derived both cortical and olfactory placodal
neurons from the same individuals with SHANK3 mu-
tations [128]. The olfactory placodal neurons had
more branched neurite and smaller somas, whereas
cortical neurons had shorter neurites [128]. To date,
protocols exist for generating many brain regions in-
cluding the cerebral cortex [74, 83, 169], ventral fore-
brain [85, 87, 88, 169], cerebellum [173], and
midbrain [174]. There are also many protocols to
generate specific cell types in 2D, including cortical
projection [70], GABAergic neurons [72, 175], and
hypothalamic neurons [176]. Combining the different
protocols makes it possible to study the interaction
between different brain regions [77, 177] and cell
types [178, 179] and how these change in ASD. How-
ever, it is important to note the tension between the
complexity of the system used and the system’s
throughput and reproducibility. Each factor and step
used in a culture system comes with some intrinsic
variability—meaning that the more factors and steps
needed, the more variable the system becomes which
can negatively impact reproducibility and throughput.
This must be taken into account when designing ex-
periments and will depend on the research questions.
Going beyond the ability of the cultures to reliably
model brain development, it is also essential to ensure that
the study is suitably powered. Studies to date have not
provided a clear power analysis and the number of indi-
viduals tend to be relatively low, with most studies having
1–4 affected individuals with rare mutations and 3–8 indi-
viduals for studies of individuals with idiopathic forms of
ASD (Table 1). A study exploring different experimental
designs of disease modeling using iPSC suggests using at
least 4 individuals with a known genetic lesion per group,
with more individuals increasing the sensitivity of the
study design [180]. The authors helpfully developed a
framework (with an accompanying software package—
iPSCpoweR) to assess the number of individuals needed
per study [180]. These experimental design and power
considerations are summarized in Fig. 1.
Limitations and future directions of stem cell
models for studying ASD
Despite their strengths mentioned above and in Table 2,
one has to recognize the limitations of these in vitro
models, as is the case with any model system. One clear
and obvious conceptual limitation is the lack of the
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ability to assess behavior. Another, more technical, limi-
tation is the difficulty to collect and maintain large co-
horts of iPSC lines, as is evident by the published
studies’ fairly small sample sizes (Table 1). This limita-
tion makes it difficult to study the effects of common
variation in ASD and limits the utility of these models
for non-personalized drug and genetic screening. There
are many efforts in the field to overcome this limitation
by generating repositories of iPSC lines that will be
available to researchers [145, 181–183]. These large re-
positories will allow researchers to use larger sample
sizes to study the effects of genetic background on ASD
and will allow them to stratify their studies based on
both symptoms and genetic background. Efforts are also
being made to increase the throughput of these models
to reduce variability and make them more amenable for
drug and genetic screens [84, 86, 184].
An additional limitation is that these models diverge
from in vivo brain development in a number of aspects.
Studies have shown that while human dorsal brain orga-
noids contain cell types and histological structures that
reflect in vivo cortex, they differ in their cell proportions
and in the complexity of their structural organization
[74, 76, 83]. Additionally, these brain organoids can
show increased metabolic stress and reduced cell sub-
type specification [78, 83]. That being said, these issues
are surmountable, and further development of these
models will need to account for these issues to bring the
in vitro models closer to in vivo development. To evalu-
ate the differences between in vitro models and in vivo
brain development, single-cell and bulk transcriptomics
can provide a quantitative roadmap for unbiased, sensi-
tive comparisons between in vitro and in vivo develop-
ment [41, 78, 83, 86]. To improve the validity of these
stem cell models, new protocols are being developed to
generate organoids which include a more complete rep-
resentation of the cell diversity found in vivo. Such
methods include fusing dorsal and ventral forebrain
organoids into so called assembloids, to incorporate
inhibitory neurons [85, 87, 88], adding growth factors
and small molecules to organoid cultures to promote
the genesis of oligodendrocytes [185, 186] and adding
cells (e.g., microglia) grown separately in 2D [187–
189]. Scaffolds are also being developed to increase
the structural accuracy of these models [190], a direc-
tion which has shown success in modeling other tis-
sues [191, 192].
Another limitation, especially for 3D cultures, is the
extended period of time it takes to generate these cul-
tures [77, 81]. For example, one study has shown that to
achieve later stages of maturation, including astrocyte
maturation, 3D cultures had to be maintained for 9
months [77]. This challenges the feasibility of using
these 3D cultures on a very large scale and considerably
slows down experimental turnover. One alternative is to
use 2D differentiations for these assays, as they have a
faster maturation rate [42, 43, 70, 71]. However, as men-
tioned earlier, these methods diverge significantly from
in vivo brain development. Research is, therefore, needed
to explore the possibility of accelerating the maturation
of the 3D models [193]. One possible way of addressing
this limitation is by increasing the oxygen accessibility of
the models. A recent study showed that increasing
Fig. 1 A framework of experimental design and power considerations
for culturing stem cell models. a Reproducibility can be determined by
cell counts, immunocytochemistry, and more recently, single-cell and
bulk sequencing. b Accuracy of the model can be determined by
immunocytochemistry, by single-cell sequencing, and by using tools
such as Transition Mapping [41]. c Cell proportion can be determined
by single-cell sequencing, immunocytochemistry, and flow cytometry.
d Biological process and region of the brain being modeled can be
determined by identifying cell populations using single-cell
sequencing and immunocytochemistry as well as by using Transition
Mapping [41]. e Power can be determined using dedicated tools such
as iPSCpoweR [180]. Image of brain adapted from Servier Medical art by
Servier under Creative Commons License 3.0 (smart.servier.com)
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oxygen accessibility to organoids increases their matur-
ation and structural complexity [177]. However, this
method is labor intensive and is not representative of the
processes in vivo. A more physiologically relevant method
would be to incorporate vasculature and a functional blood
brain barrier [194] which would allow for oxygen and nutri-
ents to permeate the entire organoid. An analogous method
is to transplant the organoids into a host organism such as
mice or rats. This method, while having a low throughput,
allowed the organoids to progressively mature and form in-
tact networks between the organoid and the host [78, 195,
196].
Conclusion
The promise of stem cell models to study both typical
and non-typical human brain development is already
coming to fruition. However, careful consideration is
needed when designing experiments using these models
by taking into account both biological, (i.e., maturity and
cell composition) and technical considerations (number
of samples, protocol variability, differentiation time) for
these models to meet their full potential.
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